Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm

Brief description of study

The purpose of this phase I study is to evaluate the safety and tolerability of MK-3475 (Pembrolizumab), a PD-1/PD-L1 blocking agent in patients with HIV using effective antiretroviral therapy with relapsed (has come back after being treated)/refractor (has not gone away with previous treatment) or disseminated AIDS-defining or non-AIDS defining malignancy.  This study will gain preliminary insight into the clinical benefits of the investigational drug across a variety of tumors.

Clinical Study Identifier: s16-01365 Identifier: NCT02595866
Principal Investigator: Mohammad Maher Abdul Hay.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.